| Role of Newman's classification in predicting outcomes in patients with crystal arthritis. | |
| | |
MedLine Citation:
|
PMID: 22218914 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The aim of the study was to evaluate the utility of Newman's classification in predicting outcomes in patients presenting with crystal arthritis. METHODS: Between January and December 2009, all patients who presented to our institution with acute crystal arthritis and were investigated with microbiological assessment of their synovial fluid were included in the study. Patients were divided into two groups depending on the fulfilment of Newman's criteria for culture-negative septic arthritis. Group 1 included patients that fulfilled Newman's B criteria. Group 2 included patients that fulfilled Newman's C criteria. A database looking at the demographics, mode of presentation, investigations, treatment and outcomes was then established and the results compared between the two groups. RESULTS: A total of 58 patients were identified (group 1: n = 13; group 2: n = 45). The average age was 71 years (range 33-96). The joint most commonly involved was the knee followed by the wrist. Clinical findings at presentation were comparable in both groups; however, WBC and C-reactive protein (CRP) were more likely to be raised in group 1. Although most patients in group 1 were treated with antibiotics (62%) there was still a higher rate of morbidity, greater use of supportive therapy and a longer hospital stay (22.3 days, SD 17.4) in comparison with group 2, where most patients were treated by observation only (76%, mean hospital stay 3.5 days, SD ± 4.4). The difference in length of hospital stay was statistically significant (p < 0.0001). CONCLUSIONS: Newman's criteria are a good indicator for prognosis in patients with crystal arthritis. However, the presence of crystals in an acutely inflamed joint does not exclude the need for supportive therapy and long hospital stay even in the absence of positive synovial fluid culture. |
| | |
Authors:
|
Ihab Hujazi; Graeme Ambler; Arvind Arora; Vikas Khanduja |
Related Documents
:
|
15699254 - Early and mid-term results of drug-eluting stent implantation in unprotected left main. 19147604 - Mortality following placement of drug-eluting and bare-metal stents for st-segment elev... 8024734 - Restenosis after vascular reconstruction. 20529974 - Long-term outcome of bifurcation stenting with drug-eluting stents. 17082944 - Cochlear implantations in visually impaired patients. 21124284 - Catheter aspiration thrombectomy during carotid stenting is safe and potentially effica... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article Date: 2012-01-05 |
Journal Detail:
|
Title: International orthopaedics Volume: 36 ISSN: 1432-5195 ISO Abbreviation: Int Orthop Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-05-16 Completed Date: 2012-09-20 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 7705431 Medline TA: Int Orthop Country: Germany |
Other Details:
|
Languages: eng Pagination: 1287-90 Citation Subset: IM |
Affiliation:
|
Department of Trauma and Orthopaedics, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Box 37, Hills Road, Cambridge, CB2 0QQ, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adult Aged Aged, 80 and over Anti-Bacterial Agents / therapeutic use Calcium Pyrophosphate / metabolism Chondrocalcinosis / classification, diagnosis*, metabolism, therapy Crystallization Debridement Female Humans Joints / metabolism, pathology*, surgery Male Middle Aged Periarthritis / classification, diagnosis*, metabolism, therapy Predictive Value of Tests Prognosis Treatment Outcome Uric Acid / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 10086-45-0/Calcium Pyrophosphate; 69-93-2/Uric Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Infections in spinal instrumentation.
Next Document: Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer.